CerRx Logo
CerRx Logo Contact Us
Home The CerRx drug pipeline The CerRx Team
Introduction to CerRx, Inc. The Biochemical Basis for the CerRx Approach to Cancer Therapy CerRx Clinical Products

CerRx Drug Pipeline

orange hexagonal buttonThe flagship in the CerRx pipeline is the intravenous (emulsion) fenretinide (4-HPR) formulation (patents issued and licensed to CerRx). Phase II studies of intravenous emulsion fenretinide are being planned with the National Cancer Institute (NCI).

yellow hexagonal buttonBuilding on the logical progression from 4-HPR single agent to a combination with a ceramide modulator (safingol), future CerRx endeavors will likely include the development of PPMP (a glucosylceramide synthase inhibitor that enhances activity of both 4-HPR and 4-HPR + safingol in preclinical studies).

Click on the chart below to view a larger version.

CerRx Drug Pipeline
© CerRx, Inc. (2009-2020)